|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
EP0637965B1
(en)
|
1991-11-26 |
2002-10-16 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
WO2010053572A2
(en)
|
2008-11-07 |
2010-05-14 |
Massachusetts Institute Of Technology |
Aminoalcohol lipidoids and uses thereof
|
|
CA2763819A1
(en)
|
2009-06-02 |
2010-12-09 |
Nian WU |
Pure peg-lipid conjugates
|
|
US8889394B2
(en)
|
2009-09-07 |
2014-11-18 |
Empire Technology Development Llc |
Multiple domain proteins
|
|
RU2014104090A
(ru)
*
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
KR102764250B1
(ko)
*
|
2015-09-14 |
2025-02-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
|
WO2018087753A1
(en)
*
|
2016-11-08 |
2018-05-17 |
Technology Innovation Momentum Fund (Israel) Limited Partnership |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
EP3781677A4
(en)
*
|
2018-04-16 |
2022-01-19 |
University of Massachusetts |
COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
|
|
US12357580B2
(en)
*
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
GB2600800B
(en)
*
|
2018-09-04 |
2023-08-16 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
GB2606038B
(en)
*
|
2018-09-04 |
2023-05-03 |
Univ Texas |
Compositions and methods for organ specific delivery of nucleic acids
|
|
CA3121191A1
(en)
*
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
US20220154222A1
(en)
*
|
2019-03-14 |
2022-05-19 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
US12365921B2
(en)
*
|
2019-05-30 |
2025-07-22 |
National University Corporation Hokkaido University |
Lipid nanoparticle
|
|
WO2022204043A1
(en)
*
|
2021-03-22 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeted delivery to cells
|
|
MX2023011227A
(es)
*
|
2021-03-22 |
2023-12-06 |
Recode Therapeutics Inc |
Composiciones y metodos para administracion dirigida a celulas.
|
|
KR20240024041A
(ko)
*
|
2021-03-23 |
2024-02-23 |
리코드 테라퓨틱스, 인크. |
세포로의 표적화 전신 전달을 위한 조성물 및 방법
|
|
US20240261440A1
(en)
*
|
2021-04-05 |
2024-08-08 |
The Board Of Regents Of The University Of Texas System |
Compositions, methods and uses for treating cystic fibrosis and related disorders
|
|
AU2022253004A1
(en)
*
|
2021-04-05 |
2023-10-12 |
Recode Therapeutics, Inc. |
Compositions, methods and uses for treating cystic fibrosis and related disorders
|
|
US20250276089A1
(en)
*
|
2022-05-03 |
2025-09-04 |
The Board Of Regents Of The University Of Texas System |
Co-delivery of inhibitory nucleic acids and genome editors for tumor therapy
|